We are pleased to announce that Alba by Quotient™ continues to grow in Europe and is now available in the Netherlands and Sweden in addition to the following geographies:

We are excited to share that our abstract titled: “Performance of a solid-phase photometric single use immunoassay microarray pr

We are pleased to share that we will be exhibiting at the 33^rd Regional Congress of the 

In May 2022, the EU implemented the new in-vitro medical devices Regulation (IVDR) to ensure the safety and performance of in-vit

Alba by Quotient™ believes in creating value for laboratories, that’s why in addition to a portfolio of high-quality blood bank reagents, we also offer:

•    Raised $51 million of new capital and reduced debt by approximately $140 million
•    Company to refocus commercial effort on Alba and expand MosaiQ into autoimmune and allergy 
 

To read the full 10-Q, please visit: quotientbd.com/page/financials-filings 

• The World Economic Forum’s New Champions Community brings together purpose driven companies of mid-size whose leadership is mindful of their impact on society and aspiring in building a better future 

Quotient hosted a key opinion leader (KOL) webinar on the current landscape and unmet needs within blood grouping and donor disease screening,